The pilot-plant will be built in Maebashi, Gunma Prefecture, and allow for the production under GMP regulations. At present, IBL does joint research with Astellas Pharma for the production of human fibrinogen from the silkworm cocoon and studies the expression of recombinant antibodies and enzymes in this organism.
IBL news release, Dec. 19, 2014
Immuno-Biological Laboratories plans pilot-plant for recombinant products expressed in silkworms